Utilizing a selective nuclear export inhibitor in relapsed refractory multiple myeloma

Presented by Suzy Graham, RN, BSN, OCN

Karyopharm Nurse Liaison

Please RSVP to Suzy as space is limited. 

866-914-9069

KaryopharmRSVP@pw.veeva.com

Suzy Graham

914-393-9239 sgraham@karyopharm.com

KAR0000677 Please reference this number during registration.

INDICATION

XPOVIO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti- CD38 monoclonal antibody.

This indication is approved under accelerated approval based onresponserate.Continuedapprovalforthisindicationmaybe contingentuponverificationanddescriptionofclinicalbenefitin a confirmatory trial.

ADVERSE REACTIONS

The most common adverse reactions (ARs) (incidence ≥20%) were thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infection.

The treatment discontinuation rate due to ARs was 27%. Reduction or interruption of XPOVIO dose occurred in 53% and 65.3% of patients, respectively. The most frequent ARs requiring permanent discontinuation in ≥ 4% of patients included fatigue, nausea, and thrombocytopenia. The rate of fatal ARs was 8.9%.